SGLT2i treatment during AKI and its association with major adverse kidney events.
Alcantar-Vallin L, Zaragoza JJ, Díaz-Villavicencio B, Hernandez-Morales K, Camacho-Guerrero JR, Perez-Venegas MA, Carmona-Morales EJ, Oseguera-Gonzalez AN, Murguia-Soto C, Chávez-Alonso G, Arredondo-Dubois JM, Orozco-Chan CE, Gómez-Fregoso JA, Rodríguez-García FG, Navarro-Blackaller G, Medina-González R, Martínez Gallardo-González A, Abundis-Mora GJ, Vega-Vega O, García-García G, Chávez-Iñiguez JS.
Alcantar-Vallin L, et al.
Front Pharmacol. 2024 Jun 12;15:1356991. doi: 10.3389/fphar.2024.1356991. eCollection 2024.
Front Pharmacol. 2024.
PMID: 38933678
Free PMC article.